by admin | Apr 4, 2019 | Cognition Therapeutic, News
Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in neurodegenerative diseases and disorders caused by membrane trafficking dysfunction, today announced that Mary Sano, Ph.D. of Mount...
by admin | Feb 19, 2019 | Cognition Therapeutic, News
Elayta Crossed Blood Brain Barrier and Reached CNS Levels Associated in Preclinical Studies with Cognitive Improvement Pittsburgh, Feb. 19, 2019 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and...
by admin | Jan 18, 2019 | Cognition Therapeutic, News
While the “War on Cancer” has made significant progress, the “War on Alzheimer’s” has proven to be a seemingly implacable foe. The societal costs of neurodegenerative diseases are enormous – Alzheimer’s disease is the most common cognitive dementia, affecting one of...
by admin | Nov 27, 2018 | Cognition Therapeutic, News
Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in neurodegenerative disorders, today announced the addition of three renowned leaders in imaging and molecular biomarkers to the...
by admin | Nov 8, 2018 | Cognition Therapeutic, News
Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on synaptic protection and restoration in Alzheimer’s disease and other neurodegenerative disorders, today announced that patient treatment has begun in the Phase 2 SHINE study of Elayta™...
by admin | Oct 24, 2018 | Cognition Therapeutic, News
Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on synaptic protection and restoration in Alzheimer’s disease and other neurodegenerative disorders, today announced its sponsorship of the Third International Symposium on Sigma-2 Receptors:...
